New pill aims to knock out flu symptoms faster

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily and personally signed Informed Consent Form (ICF) by a participant obtained prior to the conduct of any study-related procedure; 2. Males and females aged 18 to 65 years (inclusive) at the time of signing the ICF; 3. Subjects with influenza or other acute respiratory viral infections confirmed by polymerase chain reaction (PCR); 4. Presence of clinically significant signs of influenza or acute respiratory viral infections at screening: * Body temperature \>38,0 °С at randomization, with no intake NSAID within 12 hours before randomization; * Presence of at least two of the following symptoms of influenza or other acute respiratory viral infections (cough, rhinorrhea, sore throat, or a throat irritation) each rated non less than 6 points on a numeric rating scale (NRS); * Presence of at least one of the following systemic manifestations of influenza or other acute respiratory viral infections (headache, myalgia, or general weakness) rated non less than 6 points on a numeric rating scale (NRS). 5. Duration of illness from symptoms onset to administration of the first dose of investigational medical product or comparator is ≤ 48 hours; 6. No clinical indications for hospitalization at the time of study enrollment; 7. Consent to use adequate contraceptive methods throughout the study and for 30 days after study completion. The follwing subjects are eligible for inclusion in the study: * Females of childbearing potential must have a negative pregnancy test and use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives, contraceptive subdermal implant, intrauterine hormonal system, intrauterine device. Females not of childbearing potential (i.e., with a history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, comfirmed infertility, or ≥ 2 of menopause) are also eligible for participation; * Males with reptoductive potential must use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives. Males with infertility or a history of vasectomy are also eligible for participation; Exclusion Criteria: 1. Clinically significant allergic history; 2. Hypersensitivity to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any excipient contaned in the investigational medicinal product or comparator; 3. Intolerance to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any excipient contaned in the investigational medicinal product or comparator; 4. Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption; 5. Clinical suspicion of pneumonia of any etiology, or other bacterial infection (e.g. sinusitis, otitis media, urinary tract infection, meningitis, sepsis) requiring initiation for antibacterial therapy; 6. Nasal obstruction due to structural pathology, such as sequelae of nasal trauma, nasal polyps, septal deviation, or other organic causes; 7. History of vasomotor rhinitis; 8. Administration of antibiotics, antiviral (including Ingavirin), or immunomodulatory agents within 48 hours prior to study, and/or anticipated need for any of these agents during the study; 9. Vaccination within 90 days prior to study enrollment; 10. Uncontrolled diabetes mellitus; 11. Obesity, class II or III (body mass index ≥35 kg/m²); 12. Pregnancy or lactation; 13. Positive test for SARS-CoV-2 at screening; 14. History of autoimmune diseases; 15. Current or past HIV, syphilis, hepatitis B and/or C, or tuberculosis; 16. Known or suspected history of alcohol, psychotropic drug, or substance abuse or dependence; 17. History of chronic respiratory disease, including but not limited to: chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, diffuse panbronchiolitis, pulmonary emphysema, or pulmonary fibrosis; 18. Chronic heart failure, New York Heart Association (NYHA) functional class III or IV; 19. Current or past psychiatric disoder; 20. Any clinically significant cardiovascular, renal, hepatic, gastrointestinal , endocrine, or neurological disoder, including severe uncompensated chronic conditions (e.g., chronic kidney disease, chronic liver disease) or acute illness, or any other medical or psychiatric condition that, in investigator's opinion, could pose a safety risk to the subject if they participate in the study; 21. Subject's refusal to use an adequate method of contraception or to practice continuous sexual abstinence throughout the study and for 30 days after study completion; 22. Participation in another clinical trial within 3 months prior to screening; 23. Other conditions which, in the judgment of the investigator, could compromise the subject's participation in the study or pose an undue risk. Exclusion Criteria: 1. Subject's decision to withdraw from the study (withdrawal of informed consent); 2. Investigator's decision to discontinue the subject from the study in the subject's best interest; 3. Investigator-determined need for a concomitant therapy explicitly prohibited by the protocol of clinical study; 4. Subject's use of a therapy prohibited by the protocol; 5. Positive urine test for beta-human chorionic gonadotropin (β-hCG) in females of childbearing potential; 6. Lack of adequate cooperation by the subject with the investigator during the study; 7. Emergence during the study of conditions or events that jeopardize subject safety (e.g., hypersensitivity reactions, serious adverse events \[SAEs\]) or, in the investigator's medical judgment, worsen the subject's prognosis or preclude further participation in the clinical study; 8. Incorrect inclusion of a subject who does not meet the protocol-specified inclusion and/or exclusion criteria; 9. Major deviation from the treatment regimen, defined as: * Missing two or more consecutive doses of the investigational medicinal product (IMP) or comparator; * Total intake of fewer than 80% or more than 120% of the planned total number of capsules (full course includes 10 capsules); 10. Confirmed diagnosis of COVID-19; 11. Occurrence during the study of any other condition that precludes adherence to the protocol; 12. Subject's death.